TRKC
6 drugs Oncology
4
approved indications
6
Approved Drugs
6
Companies
10
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (6 companies)
✓ All 6 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (10 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Bayer 1 drug
Roche 1 drug
BLUEPRINT MEDICINES 1 drug
By Therapeutic Area
Other 3 drugs
Oncology 3 drugs
By Therapeutic Area
Other 3 drugs
VITRAKVI, ROZLYTREK, GAVRETO
Oncology 3 drugs
AUGTYRO, IBTROZI, LORBRENA
Indications Treated
ROS1-positive metastatic non-small cell lung cancer (NSCLC) in adultsNTRK gene fusion-positive solid tumors in adult and pediatric patients older than 1 monthMetastatic RET fusion-positive non-small cell lung cancerAdvanced or metastatic RET fusion-positive thyroid cancerNon-Small Cell Lung CancerSolid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutationMetastatic solid tumors with NTRK gene fusionSolid tumors with NTRK gene fusion where surgical resection is likely to result in severe morbiditySolid tumors with NTRK gene fusion that have progressed following treatment or have no satisfactory alternative treatmentsSolid Tumors